Veru (NASDAQ:VERU – Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, February 6th. Analysts expect Veru to post earnings of ($0.08) per share and ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor the evolving breast cancer competitive intelligence ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...

On Monday, Veru Inc (VERU) stock saw a decline, ending the day at $0.64 which represents a decrease of $-0.57 or -47.11% from the prior close of $1.21. The stock opened at $0.64 and touched a low of ...

Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 ...

The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...

William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...

Oppenheimer reiterated its Outperform rating and $5.00 price target for Veru Inc. (NASDAQ:VERU) shares, following the ...

Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.

Veru says its muscle-maintaining drug preserved more lean mass in older patients taking a GLP-1, but skittish investors ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...